IAS statement: Imbokodo trial must compel us to adequately resource efforts to find an HIV vaccine

Yesterday Johnson and Johnson and its global partners announced that they would discontinue the large-scale Imbokodo HIV Vaccine Trial.  Initial results showed that the vaccine did not provide significant protection against HIV infection in young women in sub-Saharan Africa. Despite this disappointing news, IAS – the International AIDS Society – emphasizes the importance of continued investment and engagement in trials to find an effective vaccine. There is still a lot to be learned from this specific study.

“We always hope for vaccine trials to result in a breakthrough because a vaccine for HIV is so direly needed. But let us not forget that the process of trial and error is the path of science,” IAS President Adeeba Kamarulzaman said.

The IAS recognizes the vital contribution of all stakeholders who contributed to the success of the scientific enquiry of the collaborative and complex study, especially the women who participated in the trial.

“My message to all involved is that these efforts were not in vain. This study offers pathways for further research that may yet prove critical,” Kamarulzaman added. “We particularly congratulate the study teams who have done a remarkable job to undertake the study during the challenges posed to data collection and analysis during COVID-19.”

“This has been a well-designed and conducted study, and there will be critical data coming from it, including probing the immune response generated by the vaccine, that will help guide future efforts,” Susan Buchbinder, IAS Governing Council member and protocol Co-Chair for the Imbokodo trial said.

“With the additional insights gained in the COVID-19 response, with concerted backing by funders and continued research, and with the political will needed, I am certain that an HIV vaccine is achievable,’’ Buchbinder added. “The IAS will continue to foster collaboration and work with partners to provide the necessary support for the development of an HIV vaccine.”

A parallel companion study, the Phase 3 Mosaico trial, will test the safety and efficacy of a different vaccine regimen among men who have sex with men and transgender individuals in North and Latin America and Europe.


About the IAS

IAS – the International AIDS Society – leads collective action on every front of the global HIV response through its membership base, scientific authority and convening power.

With its Vaccine Enterprise programme, the IAS seeks to share knowledge, foster collaboration, enable solutions and expand support critical to developing – and future access to – an HIV vaccine.

View the statement on the IAS website here.

18 May 2021 – HIV Vaccine Awareness Day

Today, the Journal of the International AIDS Society (JIAS) commemorates HIV Vaccine Awareness Day and reflects on the long-standing efforts to develop an HIV vaccine and the significance of SARS-CoV-2 vaccine development over the past year for the future of HIV vaccine research.

How HIV Vaccine R&D is enabling the rapid COVID-19 vaccine response

In this presentation, Dr. Roger Tatoud, presents the finding of an investigation led by the Enterprise to identify and characterize the ways in which HIV vaccine R&D has contributed to the early success of the COVID-19 vaccine response, the extent to which it has contributed across various dimensions, and the uniqueness of its contributions relative to other fields.

AMP studies demonstrate proof of concept of passive immunization for HIV prevention

The IAS-led Global HIV Vaccine Enterprise welcomes new results from the AMP proof-of-concept studies (HVTN 704/HPTN 085 and HVTN 703/HPTN 081) demonstrating that infusions of the broadly neutralizing monoclonal HIV antibody (bNAb) VRC01 can prevent some HIV infections.

VIDEO recording available – Making mAb Accessible webinar

VIDEO – Making monoclonal antibodies broadly accessible to communities most at risk of HIV/AIDS – What would it take?’

The video recording of the Global HIV Vaccine Enterprise and IAVI webinar to discuss challenges and opportunities on the Access to future monoclonal antibodies for HIV prevention is now available online.

HVTN 084 – Injectable HIV drug prevents infections

The IAS hosted Global HIV Vaccine Enterprise welcomes interim results showing effectiveness of long-acting injectable PrEP. New results announced today by ViiV healthcare show that injection of long-acting pre-exposure prophylaxis (PrEP) cabotegravir every two months is 89% more effective than a daily Truvada oral pill in a trial of women at increased risk of HIV acquisition.

HIV Vaccine Roadmap at AIDS 2020 Virtual!

With over 600 virtual sessions and events, AIDS 2020: Virtual will enable delegates to access and engage with the latest HIV science, advocacy and knowledge traditionally presented at the conference, while offering a range of new features made possible by the new virtual format. Biomedical prevention interventions have saved lives and helped prevent new HIV infections. However, declines in incidence remain far from UNAIDS targets. A safe and globally effective HIV vaccine remains a necessity for a durable control and end to the epidemic. Download the HIV vaccine, and vaccine research roadmap.

What years of HIV vaccine research can teach us about the search for a COVID-19 vaccine

SARS-CoV-2, the virus that causes COVID-19, has taken the world by surprise, just as HIV did in the 1980’s. However, unlike HIV, the world has come together and shown that a coordinated, global response to a pandemic is possible in record time. Many aspects of this response, including the search for a vaccine, have built upon technologies and lessons learned from recent epidemics, including HIV.

HVTN 702 Uhambo

Every year, World Immunization Week is celebrated during the last week of April with the aim of promoting the use of vaccines to protect people against infectious diseases. Although much progress has been made to develop vaccines, an HIV vaccine remains elusive. In this post we revisit one of the most promising HIV prevention vaccine studies that was prematurely halted due to lack of efficacy and highlight its critical role in informing HIV vaccine development.

“Bench to Clinic” web tool relaunched

The Enterprise is relaunching the “Bench to Clinic” web tool in the context of ongoing efficacy trials, a rich pipeline of new products and new approaches to the design and development of HIV vaccines. The tools provides an overview of the necessary steps in the process and estimates of corresponding timelines and budgets. It also drew attention to some potential challenges and provided links to relevant resources.